Matches in Nanopublications for { ?s ?p "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_provenance.
- NP417549.RAK8O_10qNPi62CK2l6YAp9z7kgn84VtDpjcsm5maImo0130_assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP417549.RAK8O_10qNPi62CK2l6YAp9z7kgn84VtDpjcsm5maImo0130_provenance.
- assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP519284.RADz19r2KJpK0TdeoHDQGbgHQ3adWB8HNUI881oI4_YMg130_assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519284.RADz19r2KJpK0TdeoHDQGbgHQ3adWB8HNUI881oI4_YMg130_provenance.
- NP519286.RAW6S7DQXw6-BSB3OK7TIJIBTHVrVGM9H1hmC4LnI2u1s130_assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519286.RAW6S7DQXw6-BSB3OK7TIJIBTHVrVGM9H1hmC4LnI2u1s130_provenance.
- NP422153.RAjAxMDhHu0bEWaJ85aBx-hkWneW9xEF7feAeVAzG5KDQ130_assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP422153.RAjAxMDhHu0bEWaJ85aBx-hkWneW9xEF7feAeVAzG5KDQ130_provenance.
- NP519285.RA-_yjidWNDxvbceJMVGnabi9VgjD9FoTtVSkUFTvtXFg130_assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519285.RA-_yjidWNDxvbceJMVGnabi9VgjD9FoTtVSkUFTvtXFg130_provenance.